

HN2576
Tumor volume (mm3)
700
600
500
400
300
200
100
0
0
5
10
15
20
25
30
Study Day
Vehicle
Tipifarnib

FIG. 1A



HN2594
Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
Study Day
Vehicle
Tipifarnib

FIG. 1B



HN5111
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
Study Day
Vehicle
Tipifarnib

FIG. 1C



HN5123
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
Study Day
Vehicle
Tipifarnib

FIG. 1D



ES0204
vehicle
Tipifarnib
Tumor volume (mm3)
Study Day
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25

FIG. 2A



ES0172
Vehicle
Tipifarnib
Tumor volume (mm3)
Study Day
900
800
700
600
500
400
300
200
100
0
0
5
10
15
20

FIG. 2B



BR1282
Tumor volume (mm3)
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
Study Day
Vehicle
Tipifarnib

FIG. 2C



BR1458
Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
Study Day
Vehicle
Tipifarnib

FIG. 2D



Vehicle
Tipifarnib
Cetuximab
Tipifarnib + Cetuximab
Tumor volume (mm3)
800
600
400
200
0
0 3 7 10 14 17 21 24 28
Study Day

FIG. 3A



Vehicle
Tipifarnib
Cisplatin
Tipifarnib + Cisplatin
Tumor volume (mm3)
1000
800
600
400
200
0
0 3 7 10 14 17 21 24 28
Study Day

FIG. 3B



Vehicle
Tipifarnib
Palbociclib
Tipifarnib + Palbociclib
Tumor volume (mm3)
1000
800
600
400
200
0
0
3
7
10
14
17
21
24
28
Study Day

FIG. 3C



Vehicle
Tipifarnib
Cetuximab
Tipifarnib + Cetuximab
Tumor volume (mm3)
2000
1600
1200
800
400
0
0 3 7 10 14 17 21 24 28
Study Day

FIG. 4A



Vehicle
Tipifarnib
Cisplatin
Cisplatin + Tipifarnib
Tumor volume (mm3)
2000
1600
1200
800
400
0
0 3 7 10 14 17 21 24 28
Study Day

FIG. 4B



Vehicle
Tipifarnib
Palbociclib
Tipifarnib + Palbociclib
Tumor volume (mm3)
2000
1600
1200
800
400
0
0
3
7
10
14
17
21
24
28
Study Day

FIG. 4C

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 11C

FIG. 11D

FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14A




FIG. 14B





FIG. 14C






FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C





FIG. 16D





All data from TCGA PanCancer Atlas studies
CUTOFF FOR OVER EXPRESSION
HNSCC
LSCC
UC
CRC
PDAC
LUAD
14
13
12
11
10
9
8
7
6
HRAS Expression RNAseq V2 (log)

FIG. 17



All data from TCGA PanCancer Atlas studies
* In TCGA with default settings
Spearman: -0.49
(p = 3.61e-33)
Pearson: -0.57
(p = 7.18e-45)
PIK3CA gene expression
HRAS gene expression

FIG. 18




FIG. 19A

FIG. 19B



All data from TCGA
PanCancer Atlas studies
CUTOFF FOR OVEREXPRESSION
PIK3CA Mutations
Wild type
Truncating
Missense
7
8
9
10
11
12
13
HRAS: mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2) (log2)
HRAS gene expression

FIG. 20